Drug development continues to advance understanding about causes of disease, as well as to innovate therapeutic modalities.
Sponsored by:
eBooks
The increasing number of breakthroughs in small molecule drug development are exciting, but corresponding workflows are complex and require much more tailored approaches to ensure successful upstream and downstream processing, drug approvals and commercialization.
On Demand Webinars
A growing proportion of drugs in the development pipeline nowadays start out life at small biotech companies, rather than big pharma businesses.
Sustainability is at the forefront of the way Lonza runs its business. Thanks to its Vision Zero initiative, it aspires to reduce emissions, water consumption and waste, as well as work without incidents.
Increasing complexity and tight timelines are putting more pressure on professionals involved in clinical drug development.
The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer syntheses that challenge innovators' timely readiness for the Clinic.
White Papers
Accelerate Tox Material Delivery and Stay on Track for IND Submission
Small molecule active pharmaceutical ingredients (APls) are becoming more molecularly complex, resulting in formidable challenges for small and emerging biotechs.
Solid form screening (SFS) encompasses the search, preparation, and characterization necessary to identify, isolate, and ensure confidence in the stability and downstream manufacturability of a lead form. In many ways, this process serves as the bridge between drug substance and drug product for new chemical entities.
Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex.